Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Operating Expenses (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Operating Expenses for 16 consecutive years, with $214.5 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Expenses rose 39.47% year-over-year to $214.5 million; the TTM value through Mar 2026 reached $777.3 million, up 35.28%, while the annual FY2025 figure was $716.6 million, 33.18% up from the prior year.
  • Operating Expenses hit $214.5 million in Q1 2026 for Corcept Therapeutics, up from $197.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $214.5 million in Q1 2026 and bottomed at $66.9 million in Q1 2022.
  • Average Operating Expenses over 5 years is $125.5 million, with a median of $117.3 million recorded in 2024.
  • Year-over-year, Operating Expenses increased 11.91% in 2022 and then soared 50.99% in 2024.
  • Corcept Therapeutics' Operating Expenses stood at $80.6 million in 2022, then grew by 28.77% to $103.7 million in 2023, then skyrocketed by 50.99% to $156.6 million in 2024, then increased by 26.18% to $197.6 million in 2025, then rose by 8.53% to $214.5 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $214.5 million, $197.6 million, and $197.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.